First Cited
Last Cited

Articles citing This Document (Page 1 of 6)

Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures
Assessment of drug–drug interaction potential with EDP ‐305, a farnesoid X receptor agonist, in healthy subjectsClinical and Translational Science
Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of ApatinibFrontiers in Pharmacology2021
PET Imaging of ABC Transporters at the Blood-Brain Barrier2021
In Vitro/In Vivo Correlation for Drug-Drug Interactions2020
Effect of Food on the Pharmacokinetics of Gliclazide 60 mg Modified Release Tablet in Healthy Caucasian VolunteersActa Marisiensis - Seria Medica2018
Genomics and Drug Transporters and Application in Drug Discovery, Delivery, and Development2018
Some Methodologic Considerations in the Assessment of Methods for Predicting Pharmacokinetic Drug-Drug InteractionsClinical Pharmacology in Drug Development2017
Summary Report of Questionnaire Survey on Current Situation and Issues of Human Mass Balance Study Using Radioisotopes in JapanJapanese Journal of Clinical Pharmacology and Therapeutics2015
Evaluation of Time-Dependent CYP3A4 Inhibition Using Human HepatocytesMethods in Pharmacology and Toxicology2014
In Vitro Characterization of Intestinal Transporter, Breast Cancer Resistance Protein (BCRP)Methods in Pharmacology and Toxicology2014
In Vitro CYP Induction Using Human HepatocytesMethods in Pharmacology and Toxicology2014
In Vitro Characterization of Renal Transporters OAT1, OAT3, and OCT2Methods in Pharmacology and Toxicology2014
Membrane Transporters in ADMEAAPS Advances in the Pharmaceutical Sciences Series2013
In Vitro Kinetic Characterization of Transporter-Mediated PermeabilityAAPS Advances in the Pharmaceutical Sciences Series2013
Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug InteractionsClinical Pharmacology and Therapeutics2021
Drug-transporter interaction testing in drug discovery and developmentWorld Journal of Pharmacology2013
Irreversible enzyme inhibition kinetics and drug-drug interactionsMethods in Molecular Biology2014
Reversible mechanisms of enzyme inhibition and resulting clinical significanceMethods in Molecular Biology2014
Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet FormulationDiabetes Therapy2021
Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical StudyClinical and Translational Science2021
Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human HepatocytesClinical Pharmacology and Therapeutics2020
The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to MidazolamClinical Pharmacology and Therapeutics2020
Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and DigoxinClinical and Translational Science2020
Test-Retest Repeatability of [F]MC225-PET in Rodents: A Tracer for Imaging of P-gp FunctionACS Chemical Neuroscience2020
Drug Interactions in the Liver2020
Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male SubjectsJournal of Clinical Pharmacology2020
Evaluation of absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitorXenobiotica2020
Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cellsBiochemical Pharmacology2020
Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and CimetidineClinical Pharmacokinetics2020
Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole)Journal of Clinical Pharmacology2020
Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activityJournal of Pharmacokinetics and Pharmacodynamics2020
Organic Cation Transporters in Human Physiology, Pharmacology, and ToxicologyInternational Journal of Molecular Sciences2020
Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentaryEuropean Journal of Pharmaceutics and Biopharmaceutics2020
Factors Affecting Successful Extrapolation of Ibuprofen Exposure from Adults to Pediatric Populations After Oral Administration of a Pediatric Aqueous SuspensionAAPS Journal2020
Drug–Drug Interaction Studies2020
Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor AntagonistJournal of Clinical Pharmacology2020
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6Pharmacology Research and Perspectives2020
Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing ConditionsAAPS Journal2020
On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant FoodAAPS Journal2019
Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairmentXenobiotica2020
Simplified Method to Determine the Efflux Ratio on P-Glycoprotein Substrates Using Three-Compartment Model Analysis for Caco-2 Cell Assay DataPharmaceutical Research2019
Effect of Food on the Pharmacokinetics of QuizartinibClinical Pharmacology in Drug Development2020
Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ modelXenobiotica2019
Absorption, disposition, metabolism and excretion of [C]mizagliflozin, a novel selective SGLT1 inhibitor, in ratsXenobiotica2019
Cardiovascular Risk Management and Hepatitis C: Combining DrugsClinical Pharmacokinetics2019
Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in HumansClinical and Translational Science2019
Management of Diabetes MellitusContemporary Cardiology2019
Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[C]Methylpurine in MiceMolecular Imaging and Biology2019
In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and ClopidogrelEuropean Journal of Drug Metabolism and Pharmacokinetics2019